Resumen de The year's new drugs and biologics 2015: Part II: Trends and highlights that marked a complicated year.

Ann I. Graul, Elisabet Cruces, Coia Dulsat, M. Tracy

• This eagle's-eye overview of the drug industry in 2015 provides insight into some of last year's top stories, including drug pricing, orphan drug development, the FDA's priority review voucher system, pipeline attrition, and the ongoing movement in M&A. We also take a look into the crystal ball and anticipate the new drugs that may reach the market in 2016.